{"id":"artemether-lumefantrine-aln","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, an artemisinin derivative, rapidly reduces parasite biomass by generating reactive oxygen species that damage parasite membranes and proteins. Lumefantrine, a biguanide-like compound, inhibits parasite heme polymerization and prevents detoxification of toxic heme, providing sustained parasite suppression. Together they achieve fast initial parasite clearance followed by complete elimination.","oneSentence":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing rapid parasite clearance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:31.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"}]},"trialDetails":[{"nctId":"NCT04767217","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study, Rwanda","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-06-14","conditions":"Uncomplicated Malaria","enrollment":528},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"artemether-lumefantrine (ALN)","genericName":"artemether-lumefantrine (ALN)","companyName":"Jhpiego","companyId":"jhpiego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing rapid parasite clearance. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}